-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Jiangxi clearly defines the classified management of Guotan drugs, among which the negotiated drugs with longer use cycle and higher treatment course cost are included in the "dual-channel" category A drug management; high clinical value, urgent need for patients, low substitution, specific drug users (major and extra larg.
Diseases or infectious diseases emergency needs, e.
) are included in Category B management, and negotiated drugs that cannot or should not be sold in pharmacies due to the policy regulations of the industry competent authorities, or are easily abused and easily lead to uncontrollable medical insurance fund expenditures, are included in Category C management, and are not included in the "Double Drugs" catego.
Channel" management sco.
Recently, the Jiangxi Provincial Medical Insurance Bureau issued a notice on printing and distributing the "Double-channel Drug Classification Management List in Jiangxi Province" to classify and manage 290 Guotan drugs, of which 86 drugs are included in dual-channel A management; 136 drugs are included in dual-channel.
Class C management; 68 drugs are managed according to Class C and are not included in the dual-channel management scope of Jiangxi Provin.
On November 23, 2021, the Jiangxi Provincial Medical Insurance Bureau issued the "Interim Measures for the Administration of Dual-Channel Negotiated Drugs in Jiangxi Provinc.
For negotiated drugs included in dual-channel management, the dual-channel drug payment policy shall be implemented; for negotiated drugs not included in dual-channel management, the medical insurance Class B drug payment policy shall be implement.
In batches, gradually included in the national medical insurance negotiation dru.
For dual-channel drugs, the "dual-channel three-determination management" of designated medical institutions, designated retail pharmacies and designated responsible physicians is implement.
On March 14, 2022, the Jiangxi Provincial Medical Insurance Bureau and other four departments jointly issued the "Notice on Further Implementing the Implementation of National Medical Insurance Negotiated Drugs", which clearly comprehensively considers clinical value, patients' needs for rational drug use, course cost burden, alternatives, factors such as the affordability of medical insurance funds, the negotiated drugs are divided into three categories for manageme.
Negotiated drugs with a long use cycle and a high course of treatment cost are included in the "dual-channel" category A drug management; those with high clinical value, urgent needs for patients, low substitution, specific drug users (serious diseases or emergency needs of infectious diseases, e.
) Negotiated drugs are included in the "dual-channel" category B drug management; negotiated drugs that cannot or should not be sold in pharmacies due to the policy regulations of the industry competent authorities, or are easily abused and easily lead to uncontrollable medical insurance fund expenditures are managed as category C, and are not included in the "dual-channel" catego.
"Management Sco.
The "Notice" clarifies that when the insured people use Class A and Class B negotiated drugs in hospital or outpatient clinics, they are included in the scope of the overall fund payment, and the current treatment policies are consiste.
For Class A and Class B negotiated drugs that are temporarily unavailable to dual-channel medical institutions, the prescriptions issued by the responsible physicians can be transferred to dual-channel pharmacies through the prescription circulation platform of the medical security department to effectively improve the availability of negotiated dru.
In addition, the annual accumulated drug expenses of the insured people using negotiated drugs shall be calculated in combination with the maximum payment limit of basic medical insurance and serious illness insurance fun.
Class A drugs are paid in a separate line, with no minimum payment line and personal payment ratio, and are paid according to the highest payment standard of medical insurance and the fixed fee policy borne by individua.
For Class B drugs, there is no minimum payment line, and the individual pays 10% first, and then pays according to the highest payment standard of medical insurance and the fixed fee policy borne by the individu.
The personal burden of the negotiated drugs can also be included in the serious illness insurance and medical assistance fund payment according to regulatio.
Diseases or infectious diseases emergency needs, e.
) are included in Category B management, and negotiated drugs that cannot or should not be sold in pharmacies due to the policy regulations of the industry competent authorities, or are easily abused and easily lead to uncontrollable medical insurance fund expenditures, are included in Category C management, and are not included in the "Double Drugs" catego.
Channel" management sco.
Recently, the Jiangxi Provincial Medical Insurance Bureau issued a notice on printing and distributing the "Double-channel Drug Classification Management List in Jiangxi Province" to classify and manage 290 Guotan drugs, of which 86 drugs are included in dual-channel A management; 136 drugs are included in dual-channel.
Class C management; 68 drugs are managed according to Class C and are not included in the dual-channel management scope of Jiangxi Provin.
On November 23, 2021, the Jiangxi Provincial Medical Insurance Bureau issued the "Interim Measures for the Administration of Dual-Channel Negotiated Drugs in Jiangxi Provinc.
For negotiated drugs included in dual-channel management, the dual-channel drug payment policy shall be implemented; for negotiated drugs not included in dual-channel management, the medical insurance Class B drug payment policy shall be implement.
In batches, gradually included in the national medical insurance negotiation dru.
For dual-channel drugs, the "dual-channel three-determination management" of designated medical institutions, designated retail pharmacies and designated responsible physicians is implement.
On March 14, 2022, the Jiangxi Provincial Medical Insurance Bureau and other four departments jointly issued the "Notice on Further Implementing the Implementation of National Medical Insurance Negotiated Drugs", which clearly comprehensively considers clinical value, patients' needs for rational drug use, course cost burden, alternatives, factors such as the affordability of medical insurance funds, the negotiated drugs are divided into three categories for manageme.
Negotiated drugs with a long use cycle and a high course of treatment cost are included in the "dual-channel" category A drug management; those with high clinical value, urgent needs for patients, low substitution, specific drug users (serious diseases or emergency needs of infectious diseases, e.
) Negotiated drugs are included in the "dual-channel" category B drug management; negotiated drugs that cannot or should not be sold in pharmacies due to the policy regulations of the industry competent authorities, or are easily abused and easily lead to uncontrollable medical insurance fund expenditures are managed as category C, and are not included in the "dual-channel" catego.
"Management Sco.
The "Notice" clarifies that when the insured people use Class A and Class B negotiated drugs in hospital or outpatient clinics, they are included in the scope of the overall fund payment, and the current treatment policies are consiste.
For Class A and Class B negotiated drugs that are temporarily unavailable to dual-channel medical institutions, the prescriptions issued by the responsible physicians can be transferred to dual-channel pharmacies through the prescription circulation platform of the medical security department to effectively improve the availability of negotiated dru.
In addition, the annual accumulated drug expenses of the insured people using negotiated drugs shall be calculated in combination with the maximum payment limit of basic medical insurance and serious illness insurance fun.
Class A drugs are paid in a separate line, with no minimum payment line and personal payment ratio, and are paid according to the highest payment standard of medical insurance and the fixed fee policy borne by individua.
For Class B drugs, there is no minimum payment line, and the individual pays 10% first, and then pays according to the highest payment standard of medical insurance and the fixed fee policy borne by the individu.
The personal burden of the negotiated drugs can also be included in the serious illness insurance and medical assistance fund payment according to regulatio.
